HS Code:
3-Quinuclidinyl benzilate (often abbreviated as QNB) falls under the category of organic compounds, specifically within the scope of heterocyclic compounds and esters. It is primarily known for its use as an anticholinergic agent and has applications in pharmacological research. Due to its potential use as a chemical warfare agent (incapacitating agent), it is strictly regulated under international agreements such as the Chemical Weapons Convention (CWC). Trade in this product is limited and heavily controlled, often restricted to research purposes under stringent licensing.
Total Trade Volume
Not publicly disclosed (due to sensitivity and regulatory restrictions)
Data from 2023
Source
Estimated data based on UN Comtrade, WTO reports, and chemical regulatory bodies
Average Rate
Not applicable (trade heavily restricted)
Highest Rate
Not applicable (often banned or controlled)
Lowest Rate
Not applicable (often banned or controlled)
Increased regulatory oversight
Stricter controls have reduced any potential illicit trade while ensuring legitimate research use under monitored conditions.
2021-2023
Focus on alternative research compounds
Due to restrictions on 3-Quinuclidinyl benzilate, pharmaceutical research is shifting toward less regulated anticholinergic compounds.
2020-2023
The Organisation for the Prohibition of Chemical Weapons (OPCW) has introduced enhanced monitoring mechanisms for Schedule 2 and 3 chemicals, including precursors and agents like 3-Quinuclidinyl benzilate.
April 2023
Further tightened trade controls and increased scrutiny on research-related imports/exports.
Countries like the United States and members of the European Union have updated their national chemical control lists to include stricter penalties for unauthorized trade of incapacitating agents.
January 2022
Reduced risk of misuse but increased compliance costs for legitimate research entities.